Table of Contents

1 Study Coverage

• 1.1 Aurora Kinase B Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Aurora Kinase B Market Size Growth Rate by Product
  • 1.4.2 AZD-2811
  • 1.4.3 CS-2164
  • 1.4.4 Danusertib
  • 1.4.5 Ilorasertib
  • 1.4.6 NMI-900
  • 1.4.7 Others
• 1.5 Market by End User
  • 1.5.1 Global Aurora Kinase B Market Size Growth Rate by End User
  • 1.5.2 Anaplastic Large Cell Lymphoma
  • 1.5.3 Kidney Cancer
  • 1.5.4 Lung Cancer
  • 1.5.5 Prostate Cancer
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Aurora Kinase B Market Size
  • 2.1.1 Global Aurora Kinase B Revenue 2014-2025
  • 2.1.2 Global Aurora Kinase B Sales 2014-2025
• 2.2 Aurora Kinase B Growth Rate by Regions
  • 2.2.1 Global Aurora Kinase B Sales by Regions
  • 2.2.2 Global Aurora Kinase B Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Aurora Kinase B Sales by Manufacturers
  • 3.1.1 Aurora Kinase B Sales by Manufacturers
  • 3.1.2 Aurora Kinase B Sales Market Share by Manufacturers
  • 3.1.3 Global Aurora Kinase B Market Concentration Ratio (CR5 and HHI)
• 3.2 Aurora Kinase B Revenue by Manufacturers
  • 3.2.1 Aurora Kinase B Revenue by Manufacturers (2014-2019)
  • 3.2.2 Aurora Kinase B Revenue Share by Manufacturers (2014-2019)
• 3.3 Aurora Kinase B Price by Manufacturers
• 3.4 Aurora Kinase B Manufacturing Base Distribution, Product Types
  • 3.4.1 Aurora Kinase B Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Aurora Kinase B Product Type
  • 3.4.3 Date of International Manufacturers Enter into Aurora Kinase B Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Aurora Kinase B Sales by Product
• 4.2 Global Aurora Kinase B Revenue by Product
• 4.3 Aurora Kinase B Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Aurora Kinase B Breakdown Data by End User

6 North America

• 6.1 North America Aurora Kinase B by Countries
  • 6.1.1 North America Aurora Kinase B Sales by Countries
  • 6.1.2 North America Aurora Kinase B Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Aurora Kinase B by Product
• 6.3 North America Aurora Kinase B by End User

7 Europe

• 7.1 Europe Aurora Kinase B by Countries
  • 7.1.1 Europe Aurora Kinase B Sales by Countries
  • 7.1.2 Europe Aurora Kinase B Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Aurora Kinase B by Product
• 7.3 Europe Aurora Kinase B by End User

8 Asia Pacific

• 8.1 Asia Pacific Aurora Kinase B by Countries
  • 8.1.1 Asia Pacific Aurora Kinase B Sales by Countries
  • 8.1.2 Asia Pacific Aurora Kinase B Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Aurora Kinase B by Product
• 8.3 Asia Pacific Aurora Kinase B by End User

9 Central & South America

• 9.1 Central & South America Aurora Kinase B by Countries
  • 9.1.1 Central & South America Aurora Kinase B Sales by Countries
  • 9.1.2 Central & South America Aurora Kinase B Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Aurora Kinase B by Product
• 9.3 Central & South America Aurora Kinase B by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Aurora Kinase B by Countries
  • 10.1.1 Middle East and Africa Aurora Kinase B Sales by Countries
  • 10.1.2 Middle East and Africa Aurora Kinase B Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Aurora Kinase B by Product
• 10.3 Middle East and Africa Aurora Kinase B by End User

11 Company Profiles

• 11.1 AbbVie Inc
  • 11.1.1 AbbVie Inc Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 AbbVie Inc Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 AbbVie Inc Aurora Kinase B Products Offered
  • 11.1.5 AbbVie Inc Recent Development
• 11.2 Advenchen Laboratories LLC
  • 11.2.1 Advenchen Laboratories LLC Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Advenchen Laboratories LLC Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Advenchen Laboratories LLC Aurora Kinase B Products Offered
  • 11.2.5 Advenchen Laboratories LLC Recent Development
• 11.3 Aeterna Zentaris Inc
  • 11.3.1 Aeterna Zentaris Inc Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Aeterna Zentaris Inc Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Aeterna Zentaris Inc Aurora Kinase B Products Offered
  • 11.3.5 Aeterna Zentaris Inc Recent Development
• 11.4 Amgen Inc
  • 11.4.1 Amgen Inc Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Amgen Inc Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Amgen Inc Aurora Kinase B Products Offered
  • 11.4.5 Amgen Inc Recent Development
• 11.5 AstraZeneca Plc
  • 11.5.1 AstraZeneca Plc Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 AstraZeneca Plc Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 AstraZeneca Plc Aurora Kinase B Products Offered
  • 11.5.5 AstraZeneca Plc Recent Development
• 11.6 Chipscreen Biosciences Ltd
  • 11.6.1 Chipscreen Biosciences Ltd Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Chipscreen Biosciences Ltd Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Chipscreen Biosciences Ltd Aurora Kinase B Products Offered
  • 11.6.5 Chipscreen Biosciences Ltd Recent Development
• 11.7 Cielo Therapeutics Inc
  • 11.7.1 Cielo Therapeutics Inc Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Cielo Therapeutics Inc Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Cielo Therapeutics Inc Aurora Kinase B Products Offered
  • 11.7.5 Cielo Therapeutics Inc Recent Development
• 11.8 Sanofi
  • 11.8.1 Sanofi Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Sanofi Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Sanofi Aurora Kinase B Products Offered
  • 11.8.5 Sanofi Recent Development
• 11.9 Sareum Holdings Plc
  • 11.9.1 Sareum Holdings Plc Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Sareum Holdings Plc Aurora Kinase B Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Sareum Holdings Plc Aurora Kinase B Products Offered
  • 11.9.5 Sareum Holdings Plc Recent Development

12 Future Forecast

• 12.1 Aurora Kinase B Market Forecast by Regions
  • 12.1.1 Global Aurora Kinase B Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Aurora Kinase B Revenue Forecast by Regions 2019-2025
• 12.2 Aurora Kinase B Market Forecast by Product
  • 12.2.1 Global Aurora Kinase B Sales Forecast by Product 2019-2025
  • 12.2.2 Global Aurora Kinase B Revenue Forecast by Product 2019-2025
• 12.3 Aurora Kinase B Market Forecast by End User
• 12.4 North America Aurora Kinase B Forecast
• 12.5 Europe Aurora Kinase B Forecast
• 12.6 Asia Pacific Aurora Kinase B Forecast
• 12.7 Central & South America Aurora Kinase B Forecast
• 12.8 Middle East and Africa Aurora Kinase B Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Aurora Kinase B Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Aurora Kinase B market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Aurora Kinase B market based on company, product type, end user and key regions.

This report studies the global market size of Aurora Kinase B in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Aurora Kinase B in these regions.
This research report categorizes the global Aurora Kinase B market by top players/brands, region, type and end user. This report also studies the global Aurora Kinase B market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AbbVie Inc
Advenchen Laboratories LLC
Aeterna Zentaris Inc
Amgen Inc
AstraZeneca Plc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Sanofi
Sareum Holdings Plc

Market size by Product
AZD-2811
CS-2164
Danusertib
Ilorasertib
NMI-900
Others
Market size by End User
Anaplastic Large Cell Lymphoma
Kidney Cancer
Lung Cancer
Prostate Cancer
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Aurora Kinase B market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Aurora Kinase B market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Aurora Kinase B companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Aurora Kinase B submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Aurora Kinase B are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Aurora Kinase B market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.